ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Cambrex will expand R&D capabilities for generic active pharmaceutical ingredients (APIs) at its Paullo, Italy, facility. The project will add a 150-m2 laboratory space as well as a research staff expansion. The company currently manufactures more than 70 generic APIs to the FDA’s current Good Manufacturing Practice quality standard. Generics account for approximately 20% of Cambrex’s sales. Earlier this year the company invested $5 million in an expansion of its laboratory facilities in Karlskoga, Sweden, augmenting process development, handling of highly potent substances, and crystallization studies.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X